 |
 |
 |
 |
 |
 |
 |
 |
Faculty by area of expertise 
|
|
|
|
Thomas Eissenberg
Professor, Director of Clinical Behavioral Pharmacology Laboratory
Contact information
Phone: (804) 827-4617
E-mail: teissenb@vcu.edu
Web site: Research lab
Education
Ph.D. (1994), McMaster University, Hamilton, Ontario, Canada
Program affiliation
Research interests
My primary area of research is the behavioral pharmacology of drugs of abuse, focusing primarily on nicotine/tobacco. My current work, funded by the U.S. NIH, involves 1) developing laboratory methods to evaluate potential reduced exposure products (PREPs) for tobacco users, and 2) understanding the knowledge, beliefs, attitudes, and effects of waterpipe tobacco smoking. In addition, I try to promote the responsible conduct of research, particularly with regard to interactions between local Investigational Review Boards (IRBs) and behavioral scientists. I have served on VCU’s IRB since August, 2000, and on VCU’s Conflict of Interest committee since 2003. I recently chaired the American Psychological Association’s Presidential Task Force on IRBs and Psychological Science, and am currently a member of the American Psychological Association’s Committee to Advance Research and the Society for Research on Nicotine and Tobacco’s Policy Committee.Selected publications
Breland, A. B., Kleykamp, B. A., & Eissenberg, T. (2006). Clinical laboratory evaluation of potential reduced exposure products for smokers. Nicotine and Tobacco Research, 8, 727-738.
Buchhalter, A. R., Acosta, M. C., Evans, S. E., Breland, A. B., & Eissenberg, T. (2005). Tobacco abstinence symptom suppression: The role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. Addiction, 100, 550-559.
Eissenberg, T., Ward, K. D., Smith-Simone, S., & Maziak, W. (2008). Waterpipe tobacco smoking on a U.S. college campus: Prevalence and correlates. Journal of Adolescent Health, 10, 526-529.
Gray, J. N., Breland, A. B., Weaver, M. F., & Eissenberg, T. (In press). Potential reduced exposure products (PREPs) for smokeless tobacco users: Clinical evaluation methodology. Nicotine and Tobacco Research, 10, 1441-1448.
Kleykamp, B. A., Jennings, J. M., Sams, C., Weaver M. F., & Eissenberg, T. (2008). The influence of transdermal nicotine on tobacco/nicotine abstinence and the effects of a concurrently administered cigarette in women and men. Experimental and Clinical Psychopharmacology, 16, 99-112.
Recent/current courses taught at VCU
- Grant Writing, graduate level
| Recent grants |
| NCI (R01 CA120142), “Waterpipe tobacco smoke: Toxicant exposure and effects.” Start date: February, 2008. Duration: 5 years. Direct costs: $2,307,038. Principal Investigator. |
| NIDA (R13 DA016409), “Society for Research on Nicotine and Tobacco Annual Meeting.” Start date: January, 2008. Duration: 5 years. Direct costs: $404,707. Principal Investigator. |
| NIDA (R01 DA024876), “Responding to the changing tobacco epidemic in the Eastern Mediterranean Region.” Start date: July, 2008. Duration: 5 years. Direct costs: $1,575,950. Co-Investigator. |
| NCI (R01 CA103827), “Clinical models for evaluating PREPs for tobacco users.” Start date: February, 2004. Duration: 5 years. Direct costs: $1,455,400. Principal Investigator. |
| Recent awards |
| Joseph Cochin Young Investigator Award, College on Problems of Drug Dependence, 2005 |
| VCU’s College of Humanities and Sciences Excellence in Scholarship Award, 2002 |
| Sponsored student grants |
| NIDA, (F31 DA018447), “Does puff topography measurement alter smoking behavior?” (M. Blank, PI). Start date: September, 2004. Duration: 3 years. |
| NIDA, (F31 DA017437), “Tobacco abstinence-induced cognitive decrements.” (B. A. Kleykamp, PI). Start date: September, 2003. Duration: 4 years. |
| NIDA, (F31 DA015570), “Evaluating Risk Reduction Products for Smokers.” (A. Breland, PI). Start date: August, 2002. Duration: 3 years. |
| NIDA, (F31 DA006052), “Gender and Nicotine Withdrawal – A Placebo Control Study.” (A.R. Buchhalter, PI). Start date: August, 2000. Duration: 2 years. |